Journal article icon

Journal article

Exacerbations of severe asthma in patients treated with mepolizumab

Abstract:
Extract: Mepolizumab, a humanised monoclonal antibody that neutralises interleukin-5, reduces exacerbations of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD) [1, 2]. The beneficial effect of treatment is most obvious in patients with a raised peripheral blood eosinophil count, a group who are at high risk of exacerbation off treatment [2, 3]. Even in this population, exacerbation rates whilst receiving mepolizumab are around one per patient per ye... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1183/13993003.01127-2018

Authors


More by this author
Institution:
University of Oxford
Department:
NDM
Sub department:
NDM Experimental Medicine
Oxford college:
Lady Margaret Hall
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Target Discovery Institute
Oxford college:
St Edmund Hall
Role:
Author
ORCID:
0000-0002-4288-5973
Expand authors...
Publisher:
European Respiratory Society Publisher's website
Journal:
European Respiratory Journal Journal website
Volume:
52
Issue:
6
Pages:
1801127
Publication date:
2018-10-13
Acceptance date:
2018-10-04
DOI:
EISSN:
1399-3003
ISSN:
0903-1936
Pmid:
30464012
Source identifiers:
948858
Language:
English
Pubs id:
pubs:948858
UUID:
uuid:68bd8800-e88d-4a0c-8b75-2591f05749cb
Local pid:
pubs:948858
Deposit date:
2019-02-06

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP